Table 1.

Select trials in NSCLC illustrating the discrepancy in treatment durations.

Trial	Checkpoint inhibitor	PD-L1 expression	Line	Duration
CA-209-003	Nivolumab	All	Any	Up to 2 years
Keynote 001	Pembrolizumab	>1%	Any	Continuous
Keynote 010	Pembrolizumab	>1%	≥2	Up to 2 years
Checkmate 153	Nivolumab	All	≥2	1 year vs. continuous
OAK	Atezolizumab	All	≥2	Continuous
Checkmate 017/057	Nivolumab	All	≥2	Continuous